8 Gene Editing Applications Moving from Lab to Clinical Use

3. CAR-T Cell Enhancement - Supercharging Cancer Immunotherapy

The integration of gene editing with CAR-T cell therapy represents a revolutionary advancement in cancer treatment, combining the precision of genetic modification with the power of engineered immune cells to create more effective and safer cancer-fighting tools. Traditional CAR-T therapy involves extracting a patient's T cells, genetically modifying them to recognize and attack cancer cells, and reinfusing them back into the patient. However, gene editing technologies like CRISPR-Cas9 have enabled researchers to make additional modifications that enhance the therapy's effectiveness and reduce side effects. These improvements include editing out genes that cause T cell exhaustion, inserting genes that help T cells survive longer in the hostile tumor environment, and removing immune checkpoint proteins that cancer cells exploit to evade detection. Clinical trials are exploring gene-edited CAR-T cells for various blood cancers and solid tumors, with early results showing improved persistence and anti-tumor activity compared to conventional CAR-T therapies. Additionally, gene editing allows for the creation of "universal" CAR-T cells from healthy donors, potentially making this therapy more accessible and cost-effective by eliminating the need for patient-specific manufacturing. Companies like Allogene Therapeutics and Cellectis are advancing these off-the-shelf approaches through clinical development, with the goal of creating standardized, immediately available cancer treatments that could benefit patients who cannot wait for personalized cell manufacturing or whose own T cells are too compromised by previous treatments.